4-(1-tert-butoxycarbonylpiperidin-4-yl)-1-naphthoic acid | 332398-36-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(1-tert-butoxycarbonylpiperidin-4-yl)-1-naphthoic acid
• 英文别名: 4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1-naphthoic acid；4-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]naphthalene-1-carboxylic acid
• CAS: 332398-36-4
• 化学式: C₂₁H₂₅NO₄
• 分子量: 355.434
• InChiKey: SUOJTAAZMOESCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Tert-butyl 4-(4-methoxycarbonylnaphthalen-1-yl)piperidine-1-carboxylate 在 lithium hydroxide 、 水 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 20.0h， 生成 4-(1-tert-butoxycarbonylpiperidin-4-yl)-1-naphthoic acid
  参考文献：
  名称：

  PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS

  摘要：

  公开号：

  EP1216239B1

文献信息

• [EN] COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)<br/>[FR] COMPOSÉS SE LIANT À LA PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9)
  申请人：PORTOLA PHARM INC

  公开号：WO2017147328A1

  公开（公告）日：2017-08-31

  The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).

  本公开涉及与PCSK9结合的新化合物、方法和组合物，从而调节PCSK9前蛋白酶酶活性。本公开的化合物包括化合物式（I）。
• [EN] PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS<br/>[FR] DERIVES DE PIPERAZINE UTILISES EN TANT QU'ANTAGONISTES DE 5-HT1B
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001023374A1

  公开（公告）日：2001-04-05

  Piperazine derivatives of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in therapy as 5-HT1B antagonists. W,Y,Ra-Reare so defined in the application.

  式(I)的哌嗪衍生物，其制备方法，包含它们的制药组合物以及作为5-HT1B拮抗剂在治疗中的用途。W，Y，Ra-Re在申请中有定义。
• Piperazine derivatives as 5-HT1B antagonists
  申请人：SmithKline Beecham p.I.c.

  公开号：US20040176388A1

  公开（公告）日：2004-09-09

  Piperazine derivatives of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in therapy as 5-HT 1B antagonists. W,Y,R a -R e are so defined in the application. 1

  公式(I)的吡哆醇衍生物，其制备方法，包含它们的制药组合物以及它们作为5-HT1B拮抗剂在治疗中的应用。其中，W，Y，Ra-Re在申请中有定义。
• COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20190119236A1

  公开（公告）日：2019-04-25

  The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).
• COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9
  申请人：SRX Cardio, LLC

  公开号：US20210032214A1

  公开（公告）日：2021-02-04

  The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I).